Replies to post #357635 on Amarin Corp Plc (AMRN)

[Number sleven]

Todd, The primary assertion in the suit is that Hikma is infringing on the R-IT patents. If a jury comes to the conclusion that the R-IT patents are valid and cover the patient population of the MARINE indication, Hikma will be forced to stop selling their generic product. DRL would be forced to withdraw from the market at that point. This is not a Hatch Waxman lawsuit. It is straight up patent infringement. If this case is not dismissed Hikma will be at risk for damages.(likely in the billions) I don't think they will roll the dice.
Sleven,